賽妥珠單抗市場規模、佔有率和成長分析：按治療適應症、給藥途徑/劑型、最終用戶和地區分類－2026年至2033年產業預測

2024 年全球 certolizumab pegol 市值為 346 億美元，預計到 2025 年將成長至 380.6 億美元，到 2033 年將成長至 815.8 億美元，在預測期（2026-2033 年）內複合年成長率為 10.0%。

全球賽妥珠單抗市場的主要驅動力是自體免疫疾病盛行率的不斷上升，以及對現有生物製藥不耐受或無反應的患者對有效治療方法的需求。該市場涵蓋品牌生物製藥的銷售、醫院處方以及針對類風濕性關節炎、克隆氏症、中軸型脊椎關節炎和斑塊型乾癬等疾病的擴展適應症。賽妥珠單抗獨特的藥理特性增強了臨床醫生對其用於治療育齡婦女的信心，進一步推動了市場需求。類風濕性關節炎覆蓋範圍和適應症的擴大導致處方量增加，尤其是在類風濕性關節炎和中軸型脊椎關節炎。此外，在偏遠地區使用預填充式注射器有助於提高農村地區的用藥依從性，而來自生物相似藥的預期競爭可能會加速新興市場的滲透。

全球賽妥珠單抗市場成長要素

隨著自體免疫疾病的日益增多，針對慢性發炎路徑特異性生物目標製劑的臨床需求顯著成長，這使得人們對塞妥珠單抗聚乙二醇酯（certolizumab pegol）作為一種有效治療選擇的興趣日益濃厚。這種持續的臨床需求促使醫療系統和醫護人員將已上市的生物製藥納入治療通訊協定，從而推動了處方量的增加，並促使生產商加大對生產和藥品獲取途徑的投入。此外，患者權益倡導和認知水平的提高增強了這些治療方法的接受度，而臨床經驗的積累和公認的治療益處也增強了臨床醫生的信心；所有這些因素共同推動了塞妥珠單抗聚乙二醇酯市場的穩步成長。

全球賽妥珠單抗市場面臨的限制因素

除了生物製藥的高昂成本外，不一致的報銷政策仍然是限制患者獲得賽妥珠單抗聚乙二醇酯（certolizumab pegol）的一大挑戰，最終阻礙了市場成長。付款者通常會實施嚴格的用藥控制並限制處方藥清單，從而降低了處方柔軟性，迫使醫療服務提供者探索替代治療方法。這些准入障礙阻礙了產品的推廣，導致分銷網路擴張受阻，並促使生產商制定方案來解決價格承受能力問題。因此，成本敏感性和不均衡的保險覆蓋體系共同阻礙了賽妥珠單抗聚乙二醇酯的廣泛應用，並限制了市場的整體成長潛力。

全球賽妥珠單抗市場趨勢

全球賽妥珠單抗市場正經歷重大變革時期，生物相似藥競爭日益激烈，重塑發炎性疾病的治療格局。隨著新參與企業推出生物相似藥，原廠藥生產商正透過提供全面的服務、病患支持舉措以及可靠的生命週期證據來強化自身市場地位，從而實現差異化競爭。支付者和醫療服務提供者越來越重視評估生物相似藥在原廠藥之外的治療價值，而臨床醫生則更關注互通性和臨床支持等因素。這種不斷變化的競爭格局正在加速客製化進入策略和策略聯盟的採用，凸顯了真實世界療效和以患者為中心的益處對於維持市場地位的重要性。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球賽妥珠單抗市場規模：依治療適應症分類

• 克隆氏症
• 類風濕性關節炎
• 乾癬性關節炎
• 僵直性脊椎炎
• 斑塊型乾癬

全球賽妥珠單抗聚乙二醇市場規模：依給藥途徑/劑型分類

• 預填充式注射器（200毫克）
• 用於復溶的冷凍乾燥粉末
• 自動注射器（Cimzia/Cimzia Starter）

全球賽妥珠單抗聚乙二醇市場規模：依最終用戶分類

• 專科診所（風濕病科、消化系統疾病科）
• 住院醫院
• 專業零售藥房

全球賽妥珠單抗聚乙二醇市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• UCB SA
• Pfizer Inc.
• AbbVie Inc.
• Amgen Inc.
• Bristol Myers Squibb
• Celgene Corporation
• Genentech, Inc.
• Sanofi SA
• Johnson & Johnson
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Regeneron Pharmaceuticals, Inc.
• Nova Biomedical Corporation
• Biogen Inc.
• Mitsubishi Tanabe Pharma Corporation
• Astellas Pharma Inc.
• GSK（GlaxoSmithKline）
• Sandoz International GmbH
• Alnylam Pharmaceuticals, Inc.

結論與建議

Global Certolizumab Pegol Market size was valued at USD 34.6 Billion in 2024 and is poised to grow from USD 38.06 Billion in 2025 to USD 81.58 Billion by 2033, growing at a CAGR of 10.0% during the forecast period (2026-2033).

The global market for certolizumab pegol is primarily driven by the increasing incidence of autoimmune diseases and the need for effective treatments for patients who cannot tolerate or respond to existing biologics. This market encompasses sales of branded biologics, hospital prescriptions, and expanding indications for conditions like rheumatoid arthritis, Crohn's disease, axial spondyloarthritis, and plaque psoriasis. Certolizumab pegol's unique pharmacologic profile enhances clinician confidence in treating women of childbearing age, further boosting demand. Improved payer coverage and expanded labeling have led to increased prescription volumes, particularly in rheumatoid and axial spondyloarthritis. Additionally, remote administration via prefilled syringes fosters adherence in rural areas, while anticipated biosimilar competition may enhance market penetration in emerging economies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Certolizumab Pegol market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Certolizumab Pegol Market Segments Analysis

Global certolizumab pegol market is segmented by therapeutic indication, administration/dosage form, end-user and region. Based on therapeutic indication, the market is segmented into Crohn's Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Plaque Psoriasis. Based on administration/dosage form, the market is segmented into Prefilled Syringe (200 mg), Lyophilized Powder for Reconstitution and Autoinjector (Cimzia/Cimzia Starter). Based on end-user, the market is segmented into Specialty Clinics (Rheumatology/Gastro), In-patient Hospital Settings and Specialty Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Certolizumab Pegol Market

The rise in autoimmune disorders has significantly heightened the clinical demand for targeted biologic therapies that specifically target chronic inflammatory pathways, leading to an increased interest in certolizumab pegol as a viable treatment option. This ongoing clinical requirement compels healthcare systems and practitioners to incorporate established biologics into their treatment protocols, facilitating expanded prescribing and prompting manufacturers to invest in production and accessibility efforts. Additionally, heightened patient advocacy and awareness enhance the acceptance of these therapies, while accumulating clinical experience and perceived therapeutic benefits bolster clinician confidence, all of which contribute to the consistent growth of the certolizumab pegol market.

Restraints in the Global Certolizumab Pegol Market

The high expense of biologic therapies, coupled with inconsistent reimbursement policies, presents ongoing challenges that limit patient access to certolizumab pegol, ultimately hindering market growth. Payers often implement strict utilization controls and place restrictions on formularies, reducing prescribing flexibility and forcing healthcare providers to explore alternative treatment options. These barriers to access diminish product uptake, create reluctance towards expanding distribution networks, and drive manufacturers to develop programs aimed at addressing affordability issues. Consequently, the combined effects of cost sensitivity and uneven coverage frameworks impede widespread adoption and restrict the overall growth potential of the certolizumab pegol market.

Market Trends of the Global Certolizumab Pegol Market

The Global Certolizumab Pegol market is experiencing a significant shift driven by the increasing competition from biosimilars, which is reshaping the landscape of therapeutic options for inflammatory conditions. As new entrants introduce biosimilar products, original manufacturers are responding by enhancing their differentiation through comprehensive service offerings, patient support initiatives, and robust lifecycle evidence to bolster their market presence. Payers and healthcare providers are placing greater emphasis on evaluating therapeutic value beyond the originator's product, while clinicians prioritize factors such as interchangeability and clinical support. This evolving competitive environment accelerates the adoption of customized access strategies and strategic collaborations, underscoring the need for real-world outcomes and patient-centric advantages to maintain market positioning.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Certolizumab pegol Market Size by Therapeutic Indication & CAGR (2026-2033)

• Market Overview
• Crohn's Disease
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Plaque Psoriasis

Global Certolizumab pegol Market Size by Administration/Dosage Form & CAGR (2026-2033)

• Market Overview
• Prefilled Syringe (200 mg)
• Lyophilized Powder for Reconstitution
• Autoinjector (Cimzia/Cimzia Starter)

Global Certolizumab pegol Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Specialty Clinics (Rheumatology/Gastro)
• In-patient Hospital Settings
• Specialty Retail Pharmacies

Global Certolizumab pegol Market Size & CAGR (2026-2033)

• North America (Therapeutic Indication, Administration/Dosage Form, End-User)
  • US
  • Canada
• Europe (Therapeutic Indication, Administration/Dosage Form, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Indication, Administration/Dosage Form, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Indication, Administration/Dosage Form, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Indication, Administration/Dosage Form, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• UCB S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nova Biomedical Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK (GlaxoSmithKline)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations